Gossamer Bio (GOSS) Stock Forecast & Price Target

$1.12

+0.03 (+2.75%)

(As of 07/26/2024 ET)

Gossamer Bio - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy
Based on 6 Analyst Ratings

Based on 6 Wall Street analysts who have issued ratings for Gossamer Bio in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 6 analysts, 1 has given a hold rating, and 5 have given a buy rating for GOSS.

Consensus Price Target

$7.88
603.13% Upside

High Forecast	$15.00
Average Forecast	$7.88
Low Forecast	$1.25

According to the 6 analysts' twelve-month price targets for Gossamer Bio, the average price target is $7.88. The highest price target for GOSS is $15.00, while the lowest price target for GOSS is $1.25. The average price target represents a forecasted upside of 603.13% from the current price of $1.12.

Type	Current Forecast 7/28/23 to 7/27/24	1 Month Ago 6/28/23 to 6/27/24	3 Months Ago 4/29/23 to 4/28/24	1 Year Ago 7/28/22 to 7/28/23
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Hold
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	5 Buy rating(s)	5 Buy rating(s)	4 Buy rating(s)	4 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	5 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$7.88	$7.88	$7.65	$6.52
Forecasted Upside	603.13% Upside	797.91% Upside	495.79% Upside	180.33% Upside

Get Gossamer Bio Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for GOSS and its competitors with MarketBeat's FREE daily newsletter.

Ad The Oxford Club

Man Who Called Nvidia at $1.10 Says Buy This Now...

In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new company could become the next to soar like Nvidia.

Watch Alex's "Next Magnificent Seven" presentation now.

GOSS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

GOSS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Gossamer Bio Stock vs. The Competition

Type	Gossamer Bio	Medical Companies	S&P 500
Consensus Rating Score	2.83	2.72	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	603.13% Upside	3,123.46% Upside	9.18% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Action	Rating	Price Target	Upside/Downside on Report Date
6/25/2024	Oppenheimer 3 of 5 stars	Initiated Coverage	Outperform	$9.00	+989.44%
6/17/2024	The Goldman Sachs Group 2 of 5 stars	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00	+1,316.41%
5/20/2024	HC Wainwright 3 of 5 stars	Reiterated Rating	Buy ➝ Buy	$10.00	+1,357.28%
5/8/2024	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$4.00	+416.06%
3/27/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$15.00	+1,204.34%
7/27/2023	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$8.00 ➝ $1.25	-0.79%
Get the Latest News and Ratings for GOSS and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Gossamer Bio and its competitors with MarketBeat's FREE daily newsletter.
3/21/2023	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Equal Weight	$2.00 ➝ $1.50	+23.97%
3/7/2023	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$5.00	+187.36%
2/28/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral
12/12/2022	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target		$7.00	+241.46%
12/7/2022	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target		$15.00 ➝ $7.00	+264.58%
12/7/2022	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Underweight
12/7/2022	Sumitomo Mitsui Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$3.00	+27.12%
12/7/2022	SVB Leerink Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Outperform	$15.00 ➝ $10.00	+323.73%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 05:39 AM ET.

GOSS Forecast - Frequently Asked Questions

What is Gossamer Bio's forecast for 2024?: According to the research reports of 6 Wall Street equities research analysts, the average twelve-month stock price forecast for Gossamer Bio is $7.88, with a high forecast of $15.00 and a low forecast of $1.25.
Should I buy or sell Gossamer Bio stock right now?: 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gossamer Bio in the last twelve months. There is currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" GOSS shares.
Does Gossamer Bio's stock price have much upside?: According to analysts, Gossamer Bio's stock has a predicted upside of 797.91% based on their 12-month stock forecasts.
What analysts cover Gossamer Bio?: Gossamer Bio has been rated by research analysts at HC Wainwright, Oppenheimer, The Goldman Sachs Group, and Wedbush in the past 90 days.
Do Wall Street analysts like Gossamer Bio more than its competitors?: Analysts like Gossamer Bio more than other "medical" companies. The consensus rating score for Gossamer Bio is 2.83 while the average consensus rating score for "medical" companies is 2.72. Learn more on how GOSS compares to other companies.